Charles G. Drake

90.4k total citations · 16 hit papers
490 papers, 40.5k citations indexed

About

Charles G. Drake is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Charles G. Drake has authored 490 papers receiving a total of 40.5k indexed citations (citations by other indexed papers that have themselves been cited), including 270 papers in Oncology, 193 papers in Immunology and 187 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Charles G. Drake's work include Cancer Immunotherapy and Biomarkers (230 papers), Immunotherapy and Immune Responses (138 papers) and Prostate Cancer Treatment and Research (109 papers). Charles G. Drake is often cited by papers focused on Cancer Immunotherapy and Biomarkers (230 papers), Immunotherapy and Immune Responses (138 papers) and Prostate Cancer Treatment and Research (109 papers). Charles G. Drake collaborates with scholars based in United States, Canada and France. Charles G. Drake's co-authors include Drew M. Pardoll, Suzanne L. Topalian, Sydney J. Peerless, Allan J. Fox, Evan J. Lipson, Dario A.A. Vignali, Angelo M. De Marzo, Fernando Viñuela, Robert A. Anders and Julie R. Brahmer and has published in prestigious journals such as Science, New England Journal of Medicine and Cell.

In The Last Decade

Charles G. Drake

478 papers receiving 39.0k citations

Hit Papers

Immune Checkpoint Blockad... 1979 2026 1994 2010 2015 2010 2007 2012 2004 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
    2015 3.1k citations Suzanne L. Topalian, Charles G. Drake et al. profile →
  2. Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
    2010 2.3k citations Charles G. Drake, Janis M. Taube et al. profile →
  3. Inflammation in prostate carcinogenesis
    2007 1.2k citations Angelo M. De Marzo, Elizabeth A. Platz et al. Nature reviews. Cancer profile →
  4. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
    2012 1.1k citations Suzanne L. Topalian, Charles G. Drake et al. profile →
  5. Role of LAG-3 in Regulatory T Cells
    2004 993 citations Xiaoyu Pan, Edward L. Hipkiss et al. profile →
  6. Prostate cancer
    2015 708 citations Charles G. Drake, Johann S. de Bono et al. profile →
  7. LAG3 (CD223) as a cancer immunotherapy target
    2017 684 citations Ariel E. Marciscano, Charles G. Drake et al. profile →
  8. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy
    2015 661 citations Andrew B. Sharabi, Michael Lim et al. profile →
  9. Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
    2013 602 citations Sofía Lyford-Pike, Shiwen Peng et al. Cancer Research profile →
  10. Mechanisms of Immune Evasion by Tumors
    2006 545 citations Charles G. Drake, Drew M. Pardoll et al. profile →
  11. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
    2014 510 citations Andrew B. Sharabi, Christopher J. Nirschl et al. Cancer Immunology Research profile →
  12. Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?
    2019 486 citations Charles G. Drake et al. profile →
  13. Treatment of Ischemic Deficits from Vasospasm with Intravascular Volume Expansion and Induced Arterial Hypertension
    1982 413 citations Charles G. Drake et al. profile →
  14. Giant Intracranial Aneurysms: Experience with Surgical Treatment in 174 Patients
    1979 401 citations Charles G. Drake profile →
  15. Cerebral Arteriovenous Malformations: Considerations for and Experience with Surgical Treatment in 166 Cases
    1979 329 citations Charles G. Drake profile →
  16. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
    2022 157 citations Charles G. Drake et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles G. Drake United States 103 18.6k 16.0k 10.0k 9.2k 6.1k 490 40.5k
Scott J. Rodig United States 85 18.7k 1.0× 10.9k 0.7× 6.9k 0.7× 1.9k 0.2× 10.5k 1.7× 347 33.8k
Claudio Doglioni Italy 83 11.6k 0.6× 4.2k 0.3× 5.7k 0.6× 1.9k 0.2× 8.6k 1.4× 475 26.8k
Elaine S. Jaffe United States 122 28.2k 1.5× 15.2k 0.9× 4.4k 0.4× 8.7k 0.9× 8.6k 1.4× 720 63.1k
Henry S. Friedman United States 95 9.0k 0.5× 4.2k 0.3× 7.9k 0.8× 5.9k 0.6× 15.0k 2.4× 567 38.4k
Franco Locatelli Italy 88 8.4k 0.5× 9.9k 0.6× 2.1k 0.2× 1.7k 0.2× 7.6k 1.2× 1.0k 33.0k
Volker Diehl Germany 82 14.0k 0.8× 6.2k 0.4× 4.5k 0.4× 5.5k 0.6× 3.8k 0.6× 696 31.2k
Thomas E. Witzig United States 101 13.5k 0.7× 6.0k 0.4× 2.8k 0.3× 2.7k 0.3× 11.2k 1.8× 778 34.1k
Lothar Kanz Germany 83 6.6k 0.4× 6.3k 0.4× 2.8k 0.3× 1.8k 0.2× 5.8k 0.9× 579 22.1k
Jedd D. Wolchok United States 119 45.3k 2.4× 29.7k 1.9× 11.0k 1.1× 1.5k 0.2× 16.2k 2.6× 568 65.0k
Martín C. Mihm United States 94 20.4k 1.1× 8.2k 0.5× 2.0k 0.2× 1.2k 0.1× 9.2k 1.5× 456 34.5k

Countries citing papers authored by Charles G. Drake

Since Specialization
Citations

This map shows the geographic impact of Charles G. Drake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles G. Drake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles G. Drake more than expected).

Fields of papers citing papers by Charles G. Drake

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles G. Drake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles G. Drake. The network helps show where Charles G. Drake may publish in the future.

Co-authorship network of co-authors of Charles G. Drake

This figure shows the co-authorship network connecting the top 25 collaborators of Charles G. Drake. A scholar is included among the top collaborators of Charles G. Drake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles G. Drake. Charles G. Drake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marshall, Catherine H., Wei Fu, Hao Wang, et al.. (2021). Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 27(6). 1623–1630. 39 indexed citations
2.
Bono, Johann S. de, Christina Guo, Bora Gürel, et al.. (2020). Prostate carcinogenesis: inflammatory storms. Nature reviews. Cancer. 20(8). 455–469. 137 indexed citations
3.
Aggen, David H., Charles G. Drake, & Brian I. Rini. (2020). Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. Clinical Cancer Research. 26(9). 2087–2095. 35 indexed citations
4.
Hurwitz, Lauren M., İbrahim Kulaç, Berrak Gümüşkaya, et al.. (2020). Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prevention Research. 13(10). 853–862. 7 indexed citations
5.
Francica, Brian J., Ali Ghasemzadeh, Anthony L. Desbien, et al.. (2018). TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors. Cancer Immunology Research. 6(4). 422–433. 67 indexed citations
6.
LaFleur, Martin W., Yuki Muroyama, Charles G. Drake, & Arlene H. Sharpe. (2018). Inhibitors of the PD-1 Pathway in Tumor Therapy. The Journal of Immunology. 200(2). 375–383. 103 indexed citations
7.
Antonarakis, Emmanuel S., Eric J. Small, Daniel P. Petrylak, et al.. (2018). Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clinical Cancer Research. 24(19). 4662–4671. 26 indexed citations
8.
Kates, Max, Thomas R. Nirschl, Nikolai A. Sopko, et al.. (2017). Intravesical BCG Induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer. Cancer Immunology Research. 5(7). 594–603. 56 indexed citations
9.
Olson, Brian M., Justin J. Jeffery, Leigh Ellis, et al.. (2017). Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells. Cancer Immunology Research. 5(12). 1074–1085. 28 indexed citations
10.
Muroyama, Yuki, Thomas R. Nirschl, Christina M. Kochel, et al.. (2017). Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment. Cancer Immunology Research. 5(11). 992–1004. 166 indexed citations
11.
Prizment, Anna E., Amy M. Linabery, Pamela L. Lutsey, et al.. (2016). Circulating Beta-2 Microglobulin and Risk of Cancer: The Atherosclerosis Risk in Communities Study (ARIC). Cancer Epidemiology Biomarkers & Prevention. 25(4). 657–664. 41 indexed citations
12.
Antonarakis, Emmanuel S., Adam S. Kibel, Evan Y. Yu, et al.. (2016). Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. Clinical Cancer Research. 23(10). 2451–2459. 60 indexed citations
13.
GuhaThakurta, Debraj, Nadeem A. Sheikh, Li-Qun Fan, et al.. (2015). Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clinical Cancer Research. 21(16). 3619–3630. 101 indexed citations
14.
Jackson, Christopher M., Christina M. Kochel, Christopher J. Nirschl, et al.. (2015). Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clinical Cancer Research. 22(5). 1161–1172. 54 indexed citations
15.
Sharabi, Andrew B., Christopher J. Nirschl, Christina M. Kochel, et al.. (2014). Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunology Research. 3(4). 345–355. 510 indexed citations breakdown →
16.
Bhavsar, Nrupen A., Jay H. Bream, Alan K. Meeker, et al.. (2014). A Peripheral Circulating TH1 Cytokine Profile Is Inversely Associated with Prostate Cancer Risk in CLUE II. Cancer Epidemiology Biomarkers & Prevention. 23(11). 2561–2567. 18 indexed citations
17.
Lyford-Pike, Sofía, Shiwen Peng, Geoffrey D. Young, et al.. (2013). Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Research. 73(6). 1733–1741. 602 indexed citations breakdown →
18.
Lipson, Evan J. & Charles G. Drake. (2011). Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. Clinical Cancer Research. 17(22). 6958–6962. 434 indexed citations
19.
Wada, Satoshi, Kiyoshi Yoshimura, Edward L. Hipkiss, et al.. (2009). Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer Model. Cancer Research. 69(10). 4309–4318. 122 indexed citations
20.
Pan, Fan, Hong Yu, Eric V. Dang, et al.. (2009). Eos Mediates Foxp3-Dependent Gene Silencing in CD4 + Regulatory T Cells. Science. 325(5944). 1142–1146. 245 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott J. Rodig Breakdown of academic impact, for papers by Claudio Doglioni Breakdown of academic impact, for papers by Elaine S. Jaffe Breakdown of academic impact, for papers by Henry S. Friedman Breakdown of academic impact, for papers by Franco Locatelli Breakdown of academic impact, for papers by Volker Diehl Breakdown of academic impact, for papers by Thomas E. Witzig Breakdown of academic impact, for papers by Lothar Kanz Breakdown of academic impact, for papers by Jedd D. Wolchok Breakdown of academic impact, for papers by Martín C. Mihm
Rankless by CCL
2026